Brentuximab Vedotin + AVD regimen significantly improves 2-year progression-free survival in advanced Hodgkin lymphoma
Background
Classical Hodgkin lymphoma (cHL), particularly advanced-stage disease (stage III/IV), remains a therapeutic challenge despite its treatability. The standard frontline regimen, ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), is limited by significant toxicities, notably pulmonary toxicity from bleomycin, and notable relapse rates. Brentuximab Vedotin (BV), an anti-CD30 antibody-drug conjugate, offers a targeted approach. Its combination with AVD (BV+AVD) has emerged as a promising alternative, aiming to enhance efficacy while mitigating specific toxicities associated with ABVD.
Study Design
This prospective, randomized, open-label study enrolled 60 patients with newly diagnosed stage III/IV classical Hodgkin lymphoma at a single center. Patients were randomized to receive either Brentuximab Vedotin combined with AVD (BV+AVD; n = 30) or standard ABVD (n = 30). The primary endpoint was 2-year progression-free survival (PFS). Secondary endpoints included PET negativity after two cycles, overall response rate (ORR), overall survival (OS), and comprehensive assessment of treatment-related toxicity.
Results
Interim analysis revealed a superior 2-year progression-free survival (PFS) rate for the BV+AVD arm compared to ABVD. Patients receiving BV+AVD achieved a 2-year PFS of 80.0%, significantly higher than the 53.3% observed in the ABVD group. This represents a substantial improvement in disease control. The BV+AVD regimen also demonstrated higher rates of PET negativity post-cycle 2, with 83.3% of patients achieving negativity versus 76.6% in the ABVD arm.
BV+AVD significantly reduced pulmonary toxicity to 6.7% compared to 23.3% with ABVD, directly addressing a major concern with bleomycin. However, BV+AVD was associated with increased hematologic toxicity, specifically neutropenia (60% vs. 40%), and a higher incidence of neuropathy (43.3% vs. 16.7%), though these adverse events were predominantly low grade and manageable.
Key Findings
- Brentuximab Vedotin + AVD achieved 80.0% 2-year PFS vs. 53.3% for ABVD in advanced cHL.
- BV+AVD showed higher
PETnegativity post-cycle 2 (83.3% vs. 76.6%). - Pulmonary toxicity was significantly lower with BV+AVD (6.7% vs. 23.3% for ABVD).
- BV+AVD led to more frequent neutropenia (60% vs. 40%) and neuropathy (43.3% vs. 16.7%).
Why It Matters
This study provides compelling evidence that Brentuximab Vedotin + AVD could become a new frontline standard for advanced classical Hodgkin lymphoma, especially for patients where bleomycin-associated pulmonary toxicity is a major concern. The significant improvement in 2-year PFS offers a more durable remission for patients. While the increased rates of neutropenia and neuropathy with BV+AVD require careful monitoring, their manageable nature suggests a favorable risk-benefit profile. This finding supports a shift in treatment paradigms, potentially allowing clinicians to de-escalate bleomycin use without compromising efficacy, and instead, leverage targeted CD30 therapy to improve long-term outcomes for a vulnerable patient population.
brentuximab-vedotin
hodgkin-lymphoma
advanced-stage
chemotherapy
cd30
oncology